Domov › Nemalobunkový karcinóm pľúc › Kalifornia › Mountain View
Klinické štúdie Nemalobunkový karcinóm pľúc v meste Mountain View, CA
21 štúdií pre Nemalobunkový karcinóm pľúc hľadá účastníkov v zariadeniach v meste Mountain View a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Prebieha náborFáza 1/2
- Stanford Cancer Institute (Melanoma/NSCLC), Stanford · 5 míľ odtiaľ
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Prebieha náborFáza 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5 míľ odtiaľ
- Stanford Cancer Institute Palo Alto, Palo Alto · 5 míľ odtiaľ
Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC
Prebieha náborFáza 3
- Stanford University, Stanford · 5 míľ odtiaľ
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Prebieha náborFáza 2
- Stanford Cancer Institute, Stanford · 5 míľ odtiaľ
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Prebieha náborObservačná štúdia
- Stanford University, Palo Alto · 5 míľ odtiaľ
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Prebieha náborFáza 2
- Stanford Cancer Institute, Stanford · 5 míľ odtiaľ
- Stanford Hospital and Clinics, Stanford · 5 míľ odtiaľ
- Stanford Hospital Investigational Drug Services, Stanford · 5 míľ odtiaľ
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Prebieha náborFáza 3
- Stanford Cancer Center, Palo Alto · 5 míľ odtiaľ
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Prebieha náborFáza 1/2
- Stanford Cancer Institute, Stanford · 5 míľ odtiaľ
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Prebieha náborFáza 1/2
- Stanford University Medical Center - Neurology, Stanford · 5 míľ odtiaľ
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Prebieha náborFáza 3
- Palo Alto Medical Foundation Research Center, Palo Alto · 5 míľ odtiaľ
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Prebieha náborFáza 1/2
- Stanford Cancer Institute, Stanford · 5 míľ odtiaľ
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Prebieha náborFáza 1/2
- Stanford University Medical Center, Stanford · 5 míľ odtiaľ
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Prebieha náborFáza 1
- Stanford University Medical Center, Palo Alto · 5 míľ odtiaľ
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Prebieha náborFáza 1
- Stanford University, Palo Alto · 5 míľ odtiaľ
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Prebieha náborFáza 1/2
- Stanford University - Stanford Cancer Institute, Stanford · 5 míľ odtiaľ
A Study of LY4175408 in Participants With Advanced Cancer
Prebieha náborFáza 1
- Stanford Medicine Cancer Center, Stanford · 5 míľ odtiaľ
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Prebieha náborFáza 1/2
- Stanford University, Stanford · 5 míľ odtiaľ
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Prebieha náborFáza 1/2
- Stanford Women's Cancer Center, Palo Alto · 5 míľ odtiaľ
Engagement of Veterans With Lung Cancer
Prebieha nábor
- Veterans Affairs Palo Alto Health Care System (VAPAHCS), Palo Alto · 5 míľ odtiaľ
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Prebieha náborObservačná štúdia
- Massive Bio SYNERGY-AI site, Stanford · 5 míľ odtiaľ
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Prebieha náborFáza 1
- Stanford University, Stanford · 5 míľ odtiaľ
Štúdie Nemalobunkový karcinóm pľúc v iných mestách
- Houston, TX145 štúdií
- New York City, NY121 štúdií
- Arlington, VA104 štúdií
- Nashville, TN97 štúdií
- Boston, MA90 štúdií
- Los Angeles, CA87 štúdií
- St. Louis, MO73 štúdií
- Chicago, IL61 štúdií
- Baltimore, MD60 štúdií
- San Antonio, TX59 štúdií
- Columbus, OH57 štúdií
- Washington, DC55 štúdií
Iné štúdie v Mountain View
- Rakovina (všetky typy)40 štúdií
- Rakovina prsníka26 štúdií
- Metastatická rakovina25 štúdií
- Akútna myeloidná leukémia19 štúdií
- Rakovina vaječníkov19 štúdií
- Porucha autistického spektra17 štúdií
- Rakovina pľúc17 štúdií
- Rakovina prostaty15 štúdií
- Srdcové zlyhanie15 štúdií
- Autizmus13 štúdií
- Akútna lymfoblastová leukémia13 štúdií
- Kolorektálny karcinóm13 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.